Literature DB >> 17990346

Rectal cancer treatment: improving the picture.

Juan A Diaz-Gonzalez1, Leire Arbea, Javier Aristu.   

Abstract

Multidisciplinary approach for rectal cancer treatment is currently well defined. Nevertheless, new and promising advances are enriching the portrait. Since the US NIH Consensus in the early 90's some new characters have been added. A bird's-eye view along the last decade shows the main milestones in the development of rectal cancer treatment protocols. New drugs, in combination with radiotherapy are being tested to increase response and tumor control outcomes. However, therapeutic intensity is often associated with toxicity. Thus, innovative strategies are needed to create a better-balanced therapeutic ratio. Molecular targeted therapies and improved technology for delivering radiotherapy respond to the need for accuracy and precision in rectal cancer treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17990346      PMCID: PMC4205427          DOI: 10.3748/wjg.v13.i44.5805

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  81 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

Authors:  J-P Machiels; C Sempoux; P Scalliet; J-C Coche; Y Humblet; E Van Cutsem; J Kerger; J-L Canon; M Peeters; S Aydin; S Laurent; A Kartheuser; B Coster; S Roels; J-F Daisne; B Honhon; L Duck; C Kirkove; M-A Bonny; K Haustermans
Journal:  Ann Oncol       Date:  2007-01-05       Impact factor: 32.976

3.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

4.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

5.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial.

Authors:  J F Bosset; V Magnin; P Maingon; G Mantion; E P Pelissier; M Mercier; G Chaillard; J C Horiot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

Review 7.  Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.

Authors:  Carolyn I Sartor
Journal:  Nat Clin Pract Oncol       Date:  2004-12

8.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Authors:  N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

9.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.

Authors:  Kathy L Baglan; Robert C Frazier; Di Yan; Raywin R Huang; Alvaro A Martinez; John M Robertson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

10.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

View more
  3 in total

1.  Pilot study of a clinical pathway implementation in rectal cancer.

Authors:  Esther Uña; Francisco López-Lara
Journal:  Clin Med Insights Oncol       Date:  2010-10-12

2.  Endorectal ultrasound does not reliably identify patients with uT3 rectal cancer who can avoid neoadjuvant chemoradiotherapy.

Authors:  Ron Shapiro; Usama Ahmed Ali; Ian C Lavery; Ravi P Kiran
Journal:  Int J Colorectal Dis       Date:  2013-02-02       Impact factor: 2.571

3.  Dosimetric Comparison between Intensity Modulated Radiotherapy and 3 Dimensional Conformal Radiotherapy in the Treatment of Rectal Cancer

Authors:  David K Simson; Swarupa Mitra; Parveen Ahlawat; Manoj Kumar Sharma; Girigesh Yadav; Manindra Bhushan Mishra
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.